Intero Biosystems wins TechCrunch Disrupt 2026 Startup Battlefield with gut organoid platform

A gut-on-a-chip rival takes the prize

Intero Biosystems has won the Startup Battlefield competition at TechCrunch Disrupt 2026 in San Francisco, earning the Startup Battlefield Cup and a $100,000 prize. According to TechCrunch, the company is a Denver-based startup founded by Charlie Childs and Madeline Eiken that spun out of the University of Michigan.

Rather than a software pitch, the winning entry was biological: Intero grows human intestinal organoids about one millimetre in size, lab-built tissue that behaves like the human gut. The idea is to give researchers a way to observe how drugs and other compounds might affect the body before any testing in people. Its flagship product, GastroScreen, is sold to pharmaceutical, biotech, food and chemical companies for exactly that kind of screening work.

How the competition unfolded

Twenty startups were chosen from the wider Startup Battlefield 200 cohort and pitched over three days, each delivering a live demo in front of venture capitalists and technology executives acting as judges, TechCrunch reports. Editors then reviewed the judges' notes and narrowed the field to five finalists: Apate, Flox Intelligence, Intero Biosystems, Industrial Next and Satlyt.

The final round was decided by a panel made up of Alexa von Tobel of Inspired Capital, Chi-Hua Chien of Goodwater Capital, Dayna Grayson of Construct Capital, Karl Alomar of M13 and Stacy Brown-Philpot of Cherryrock Capital.

The runner-up sends AI after scammers

Second place went to Apate, an Australian startup founded by Dali Kaafar, who developed the concept during research at Macquarie University in Sydney. Apate runs fleets of thousands of AI agents that pose as tempting victims for criminals: they pick up scam calls, reply to dubious messages and emails, click phishing links and join social media groups to draw fraudsters into wasting their effort. Alongside access to this agent fleet, customers receive an insights portal with analytics on the scams targeting their end users, employees, brands and products.

Why it matters

The Battlefield stage has historically been an early signal. TechCrunch notes that past winners and finalists include Trello, Discord, Cloudflare and Mint, and that across more than 1,700 alumni the program's companies have collectively raised over $30 billion and produced more than 200 successful exits. A win here is less about the $100,000 check and more about joining a lineage that investors watch.

For Intero Biosystems, the timing is useful. Drug development is expensive partly because promising compounds often fail late, when they finally meet human biology. Organoid-based screening is one of the approaches being explored to catch those failures earlier and more cheaply, and GastroScreen positions the young company squarely in that market, with customers already spanning pharma, food and chemicals.

The runner-up result is also telling. A competition with an AI-scam-baiting startup placing second reflects how much of the current startup landscape is organised around AI agents, while the top prize going to lab-grown tissue is a reminder that biotech tooling remains one of the areas where startups can still build something with no obvious software analogue. Both companies now have a Disrupt finale behind them and a considerably larger audience in front of them.